← All trials
NCT04429191
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2020
- Primary completion
- Feb 15, 2021
- Completion date
- May 8, 2021
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jasper Therapeutics, Inc.Lead sponsor
- University of WashingtonOverall official - principal investigator
- University of UtahOverall official - principal investigator
- City of Hope National Medical CenterOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.